

University of Groningen

Bayesian inference of the sites of perturbations in metabolic pathways via Markov chain Monte Carlo

Jayawardhana, Bayu; Kell, Douglas B.; Rattray, Magnus

Published in:
Bioinformatics

DOI:
[10.1093/bioinformatics/btn103](https://doi.org/10.1093/bioinformatics/btn103)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2008

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Jayawardhana, B., Kell, D. B., & Rattray, M. (2008). Bayesian inference of the sites of perturbations in metabolic pathways via Markov chain Monte Carlo. *Bioinformatics*, 24(9), 1191-1197.
<https://doi.org/10.1093/bioinformatics/btn103>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Bayesian inference of the sites of perturbations in metabolic pathways via Markov chain Monte Carlo

Bayu Jayawardhana^{1,2,*}, Douglas B. Kell^{1,2} and Magnus Rattray³¹Manchester Interdisciplinary Biocentre, The University of Manchester, Manchester M1 7DN, ²School of Chemistry, The University of Manchester, Manchester M13 9PL and ³School of Computer Science, The University of Manchester, Manchester M13 9PL, UK

Received on January 29, 2008; revised on February 22, 2008; accepted on March 15, 2008

Advance Access publication March 20, 2008

Associate Editor: Thomas Lengauer

ABSTRACT

Motivation: Genetic modifications or pharmaceutical interventions can influence multiple sites in metabolic pathways, and often these are 'distant' from the primary effect. In this regard, the ability to identify target and off-target effects of a specific compound or gene therapy is both a major challenge and critical in drug discovery.

Results: We applied Markov Chain Monte Carlo (MCMC) for parameter estimation and perturbation identification in the kinetic modeling of metabolic pathways. Variability in the steady-state measurements in cells taken from a population can be caused by differences in initial conditions within the population, by variation of parameters among individuals and by possible measurement noise. MCMC-based parameter estimation is proposed as a method to help in inferring parameter distributions, taking into account uncertainties in the initial conditions and in the measurement data. The inferred parameter distributions are then used to predict changes in the network via a simple classification method. The proposed technique is applied to analyze changes in the pathways of pyruvate metabolism of mutants of *Lactococcus lactis*, based on previously published experimental data.

Availability: MATLAB code used in the simulations is available from ftp://anonymous@dbkweb.mib.man.ac.uk/pub/Bioinformatics_BJ.zip

Contact: bayujw@ieee.org

Supplementary information: Supplementary data are available at *Bioinformatics* online.

1 INTRODUCTION

Drug discovery is now recognized as a problem of integrative systems biology requiring genome-wide analyses (see, e.g. Butcher, 2005; Dobson and Kell, 2008; Williams, 2005). In particular, genomics, transcriptomics, proteomics and metabolomics are being exploited to identify the mode-of-action and toxicity of possible compounds.

A number of articles describe genome-wide studies for detecting mode-of-action (Baetz *et al.*, 2004; Clarke *et al.*, 2001; Giaever *et al.*, 1999; Marton *et al.*, 1998; Parsons *et al.*, 2004, 2006). For instance, chemical-genetic profiling (Parsons

et al., 2004, 2006) and genomic screening via induced haploinsufficiency (Baetz *et al.*, 2004; Giaever *et al.*, 1999) have been proposed to detect the sites of interaction of a compound in biochemical pathways. These techniques compare a large number of mutant strains or induced haploinsufficient organisms for hypersensitivity to a set of compounds. The strains that show greater sensitivity to a compound are used to identify the implicated pathways. This approach relies on the availability of large numbers of mutants or haploinsufficient strains.

A related approach is to use DNA microarray analysis for validating drug targets and off-targets as pursued by Betts *et al.* (2002) and Marton *et al.* (1998). Gene-expression profiles from the untreated and the drug-treated cells are analyzed and clustered based on the levels of expression. The functionality of genes which have large changes in their expression level is taken to indicate the chemical pathway(s) affected by the compound. Based on a similar principle, the use of proteomics in mode-of-action studies involves the identification of proteins that are significantly altered in the drug-treated organism (Chapal *et al.*, 2004).

Metabolomics studies have been performed from a similar perspective (Aranibar *et al.*, 2001; Ott *et al.*, 2003) and knowledge of metabolite transactions and metabolomics are also important in drug discovery (Kell, 2006). The metabolites represent the product of biochemical pathways in an organism and, potentially, can be used to infer the changes in the activities of enzymes in specific chemical pathways consequent upon pharmacological or genetic perturbations.

In metabolomics, one typically observes the metabolite concentrations or fluxes in a quasi-steady state. Because of the rapid turnover of cellular pools, it is fairly difficult to extract the metabolites reliably during transients, as these can occur on a time scale smaller than the ability to inhibit metabolism. Therefore, only steady-state data will be considered in this article, although the technique is sufficiently general to deal with time-series data where they exist.

Given measurement data statistics and a kinetic model of the metabolic pathways, we will use Bayesian inference to reflect the degree of uncertainty in the model parameters due to uncertainties in the measurements and in the initial conditions. We show that by comparing the inferred parameter distribution of the normal and drug-induced metabolic pathways,

*To whom correspondence should be addressed.

significant parameter changes can be identified and such perturbations can be taken to reflect the mode-of-action of a drug.

Simulation results using the glycolytic pathway of *Saccharomyces cerevisiae* show the effectiveness of the proposed method to predict perturbations with reasonable accuracy and high sensitivity. The technique is then applied to analyze changes in the pathways of pyruvate metabolism of mutants of *Lactococcus lactis*, based on experimental data taken from Hoefnagel *et al.* (2002).

Coleman and Block (2006) and Battogtokh *et al.* (2002) showed how the Markov Chain Monte Carlo (MCMC) strategy can be used to estimate the posterior distribution of parameters in non-linear systems described by differential equations. However, due to the nature of the problems considered in those papers, our method uses several features that are not available there. First, we focus on steady-state data without any information about the sampling time. Secondly, our technique deals with observable external variables that are not components of the state vector but that are parts of the state equations. Thirdly, metabolic pathways have stoichiometric constraints called moiety conservations and therefore parameter distributions and MCMC proposals should respect these constraints.

Liebermeister and Klipp (2006) have introduced a Bayesian inference method for parameter estimation in systems biology models. They approximate the posterior distribution by a Gaussian distribution centered around a local maximum of the posterior. Their approach assumes that the problem of interest has a unimodal and localized posterior distribution which may not be the case in complex systems such as metabolic pathways, especially when data are scarce. Tamaddoni-Nezhad *et al.* (2006) provide an alternative way to infer drug inhibitory effects in metabolic pathways using inductive logic programming. They construct logic-based reasonings based on the relative changes in metabolite concentrations and assume unidirectional reactions. This over-simplification can fail to recognize the effect of feedback mechanisms, cofactors and reversible reactions on the behavior of metabolites. A recent related work applying MCMC to systems biology, due to Vyshemirsky and Girolami (2007), implements MCMC for model selection whereas here we focus on parameter estimation and identifying significant parameter changes.

2 METHODS

2.1 Problem formulation and parameter estimation

Leaving aside stochastic systems in which the number of molecules is insufficiently large to be approximated by a continuous quantity, a kinetic model of metabolic pathways is conveniently cast in terms of coupled ordinary differential equations (ODE) in a state space form:

$$\begin{aligned}\dot{x} &= f(x, y_{\text{ext}}, \theta, t), & x(0) &= x_0, \\ y_{\text{int}} &= h(x, t),\end{aligned}\quad (1)$$

subject to M algebraic constraints:

$$\begin{aligned}\sum_{i \in A_j} x_i(t) &= C_j, & j &= 1, 2, \dots, M, \forall t \\ A_j \cap A_k &= \emptyset & \text{whenever } j \neq k\end{aligned}\quad (2)$$

where x denotes the metabolite concentrations, θ are the system parameters, y_{ext} are the observable external metabolite fluxes and concentrations, y_{int} are the observation variables and x_0 is the initial state of the model. For the j th algebraic constraint, A_j is the index set of components of x and C_j is a positive constant. In the above formulation, the function f represents the enzyme kinetics laws governing the reactions while the function h represents the observation data that are normally full or partial information on the metabolite concentrations and fluxes.

In kinetic modeling of metabolic pathways, the M algebraic constraints in (2) are called moiety conservations. These are groups of variables whose overall quantities are assumed to be constant throughout the time course (Hofmeyr *et al.*, 1986). The conservation of adenine and pyridine nucleotide moieties are examples.

Suppose that for some θ , y_{ext} and x_0 , the state Equations (1), (2) converge to a steady state. Let us denote the steady-state value by x_{ss} . The dependence of x_{ss} on θ , y_{ext} and x_0 implies that the corresponding steady-state observation y_{ss} can be described as a mapping from $(\theta, y_{\text{ext}}, x_0)$. In other words, $y_{ss} = g(\theta, y_{\text{ext}}, x_0)$ for some function g . Note that it is generally difficult to derive the function g analytically. Hence, one is forced to do numerical simulations of the kinetic model to obtain the steady-state values of the observables.

It is also assumed that the initial state x_0 and the system parameters θ are also uncertain and therefore probabilistic quantities. Let the prior distribution of x_0 be denoted by $p_{x_0}(\cdot)$ and the prior distribution of θ be denoted by $p_\theta(\cdot)$. The prior distributions represent our best knowledge or estimate of the distribution of x_0 and θ before making any observations of the system. Log-normal, gamma or Gaussian distributions expanded around parameters obtained from *in vitro* experiments are some possible choices for these priors. For initial states that are subject to a linear constraint, a Dirichlet distribution can be used along with a scale parameter. For the vaguest parameters and initial states we use uniform distributions with estimated lower and upper bounds.

The measurement data are summarized by statistical models D_{int} and D_{ext} with distribution functions $p_{\text{int}}(\cdot)$ and $p_{\text{ext}}(\cdot)$ that capture the statistics of a sufficiently large number of steady-state observations y_{ss} and external observations y_{ext} , respectively. We use distribution functions, instead of a set of data points, because steady-state measurement data published in the literature are often summarized by means and SDs. These are naturally mapped onto a Gaussian distribution. Note that the distributions represent the metabolism of an aggregation of cells, where each cell has a different steady state (the ODEs give the unicellular kinetic model) (Davey and Kell, 1996). Our model is a simplification in which we assume a single ODE with a measurement distribution capturing all sources of experimental variation.

The Bayesian inference problem (see, e.g. Gelman, 2004) asks whether we can compute the posterior distribution $p(\theta | D_{\text{int}}, D_{\text{ext}})$. Define the conditional distribution of θ given $(D_{\text{int}}, D_{\text{ext}})$ by

$$p(\theta | D_{\text{int}}, D_{\text{ext}}) = \frac{p(\theta, D_{\text{int}}, D_{\text{ext}})}{p(D_{\text{int}}, D_{\text{ext}})}$$

$$\text{where } p(\theta, D_{\text{int}}, D_{\text{ext}}) = \int \int p_{\text{int}}(g(\theta, y_{\text{ext}}, x_0) | \theta, y_{\text{ext}}, x_0) p(\theta, x_0) p_{\text{ext}}(y_{\text{ext}}) dx_0 dy_{\text{ext}}.$$

By prior independence of θ and x_0 , we can write

$$p(\theta, D_{\text{int}}, D_{\text{ext}}) = p_\theta(\theta) \int \int p_{\text{int}}(g(\theta, y_{\text{ext}}, x_0) | \theta, y_{\text{ext}}, x_0) p_{x_0}(x_0) p_{\text{ext}}(y_{\text{ext}}) dx_0 dy_{\text{ext}}. \quad (3)$$

Since $p(D_{\text{int}}, D_{\text{ext}})$ is a normalizing constant, the posterior distribution $p(\theta | D_{\text{int}}, D_{\text{ext}})$ is proportional to the right-hand side of (3).

The integral on the right hand side of (3) is the likelihood function $p(D_{\text{int}}, D_{\text{ext}} | \theta)$. It depends on the existence of steady-state values in the

dynamical equations and with parameter θ , for *all* sampled initial conditions x_0 . This condition creates a problem since most non-linear systems have unstable regions (including oscillatory behavior). For a given θ , y_{ext} , x_0 , let us define $p(D_{\text{int}} | \theta, y_{\text{ext}}, x_0) = 0$ if no steady state is reached and $p(D_{\text{int}} | \theta, y_{\text{ext}}, x_0) = p_{\text{int}}(g(\theta, y_{\text{ext}}, x_0))$ if a steady state is obtained. Then this problem can be avoided with the likelihood function given by

$$p(D_{\text{int}}, D_{\text{ext}} | \theta) = \int \int p(D_{\text{int}} | \theta, y_{\text{ext}}, x_0) p_{x_0}(x_0) p_{y_{\text{ext}}}(y_{\text{ext}}) dx_0 dy_{\text{ext}}. \quad (4)$$

MCMC can be used to draw samples from the posterior distribution $p(\theta | D_{\text{int}}, D_{\text{ext}})$ and use it to approximate various statistical properties related to $p(\theta | D_{\text{int}}, D_{\text{ext}})$, for example, approximating the confidence interval, median and expected value. Coleman and Block (2006) and Battogtokh *et al.* (2002) give an overview of the MCMC technique applied to non-linear systems. Various techniques for MCMC can be found in Gelman (2004) and Spiegelhalter *et al.* (1996). In this work we use a standard Metropolis–Hastings algorithm.

In order to draw samples from the posterior distribution using MCMC, we would like to avoid dealing explicitly with (4) since the integral that appears on the right-hand side is computationally intractable. Notice that this integral corresponds to the marginalization of $p(D_{\text{int}} | \theta, y_{\text{ext}}, x_0) p_{x_0}(x_0) p_{y_{\text{ext}}}(y_{\text{ext}})$ over x_0 and y_{ext} . Therefore, drawing samples from the posterior distribution $p(\theta | D_{\text{int}}, D_{\text{ext}})$ is equivalent to getting samples from

$$p(D_{\text{int}} | \theta, y_{\text{ext}}, x_0) p_{x_0}(x_0) p_{y_{\text{ext}}}(y_{\text{ext}}) p_{\theta}(\theta) \quad (5)$$

and marginalizing the samples over the initial state x_0 and over the external variables y_{ext} . We will refer to (5) as the target distribution $p_{\text{target}}(w)$ where $w = (\theta, y_{\text{ext}}, x_0)$.

In this article, we use the Metropolis–Hastings algorithm to generate several parallel Markov chains and the convergence of the parallel chains to a target distribution is monitored using the measure proposed by Gelman (2004). Details about the prior and proposal distributions (including those for conserved variables), the Metropolis–Hastings algorithm, and the convergence measure are given in the Supplementary Material.

2.2 Prediction of perturbations

The method described so far enables us to approximate the distribution of the system parameters given measurement data summarized by D_{int} and D_{ext} . This leads to the next problem where one has two measurement datasets that we may summarize as $(D_{\text{int}}, D_{\text{ext}})_{\text{normal}}$ and $(D_{\text{int}}, D_{\text{ext}})_{\text{perturbed}}$ corresponding to two different conditions that one may take as a reference state and a perturbed state, respectively.

By using MCMC, we can estimate the posterior distribution for the normal (wild-type) organism $p(\theta | (D_{\text{int}}, D_{\text{ext}})_{\text{normal}})$ and the posterior distribution for the drug-treated (mutant) organism $p(\theta | (D_{\text{int}}, D_{\text{ext}})_{\text{perturbed}})$. Given these two posterior distributions, one can compare both distributions to infer the effect of the perturbation.

Let the subscript i denote the index of element in θ . Then we can infer whether the enzymatic reaction with parameter θ_i has been perturbed by computing

$$p(\theta_i, \text{perturbed} > \theta_i, \text{normal} | (D_{\text{int}}, D_{\text{ext}})_{\text{normal}}, (D_{\text{int}}, D_{\text{ext}})_{\text{perturbed}}) := \int \int p(\theta_i, \text{perturbed} > \theta_i, \text{normal} | (D_{\text{int}}, D_{\text{ext}})_{\text{perturbed}}) p(\theta_i, \text{normal} | (D_{\text{int}}, D_{\text{ext}})_{\text{normal}}) d\theta_i, \text{normal} d\theta_i, \text{perturbed} \quad (6)$$

where $p(\theta_i | (D_{\text{int}}, D_{\text{ext}}))$ is the marginalization of $p(\theta | (D_{\text{int}}, D_{\text{ext}}))$ over the complement of θ_i . The above method was used by Liu *et al.* (2006) to determine the significance of differential gene expression in samples exposed to a treatment compared with those from a control.

For brevity, we use the notation $p(\theta_i, \text{perturbed} > \theta_i, \text{normal})$ to represent the left-hand term of (6).

Suppose that the MCMC samples for both cases are given by $w_{\text{normal}}(n)$ and $w_{\text{perturbed}}(n)$ where $n = 1, 2, \dots, N$ and N is the total number of samples. Then (6) can be approximated by

$$p(\theta_i, \text{perturbed} > \theta_i, \text{normal}) \approx \frac{1}{N} \sum_{n=1}^N \chi(w_{i, \text{perturbed}}(n) - w_{i, \text{normal}}(n))$$

where w_i is the i th component of w and χ is an indicator function given by $\chi(s) = 1$ for all $s \geq 0$ and $\chi(s) = 0$ elsewhere.

Since $p(\theta_i, \text{normal} > \theta_i, \text{perturbed}) = 1 - p(\theta_i, \text{perturbed} > \theta_i, \text{normal})$, the MCMC samples can be classified into three classes based on the value of $p(\theta_i, \text{perturbed} > \theta_i, \text{normal})$ with a cut-off $0 < \varepsilon < 0.5$:

- (A1) If $p(\theta_i, \text{perturbed} > \theta_i, \text{normal}) > 0.5 + \varepsilon$ then $\theta_i, \text{perturbed}$ is up-regulated;
- (A2) If $p(\theta_i, \text{perturbed} > \theta_i, \text{normal}) < 0.5 - \varepsilon$ then $\theta_i, \text{perturbed}$ is down-regulated;
- (A3) Otherwise $\theta_i, \text{perturbed}$ is unchanged.

This classification can be used to predict whether the enzymatic reaction which corresponds to the parameter θ_i is up-regulated, relatively unchanged or down-regulated in the perturbed case compared to the normal one.

In the next section, an optimal ε is computed based on the glycolysis pathway model of 16 strains of *in-silico* organism. A total of 240 ordered pairs of datasets are obtained from the permutation of 16 sets of MCMC samples. By considering the classification of these pairs of datasets for being up-regulated and for being not up-regulated, an receiver operating characteristics (ROC) curve (Broadhurst and Kell, 2006) can be drawn by varying ε . Note that if one computes an ROC curve that compares the case of being down-regulated and being not down-regulated, the symmetry of the classification algorithm and the symmetry of the permuted ordered pair of datasets ensure that the same curve is obtained. If the accuracy acc is defined by $\text{acc} = c_1 \text{TPR} + c_2 \text{TNR}$ where TPR is the true positive rate (sensitivity), TNR is the true negative rate (specificity), and c_1, c_2 are the weighting constants, the optimal ε that maximizes acc can be found from the ROC curve.

3 RESULTS

3.1 Glycolytic pathways in *Saccharomyces cerevisiae*

In this subsection, the perturbation analysis is evaluated using simulated glycolysis data. The glycolysis model is taken from Pritchard and Kell (2002) and Teusink *et al.* (2000).

The parameters are the limiting step constants V_{max} and the concentrations of external glucose, F26BP, glycerol and ethanol. The prior distributions for V_{max} are log-normal distributions with the log-mean values taken from the *in vitro* measurements presented by Teusink *et al.* (2000) and the log-variance values set between 0.4805 and 7.6872.¹ The prior distribution for the concentrations of external glucose, F26BP, glycerol and ethanol are uniform distributions with intervals: (0.01, 1000) for external glucose, (0.001, 10) for F26BP, (0.01, 100) for glycerol and (0.01, 10) for ethanol. The prior distributions for initial metabolite concentrations are uniform distributions.

Following the method described in Section 2.1, MCMC is used to draw samples from the target distribution $p_{\text{target}}(w)$ in Equation (5). This implies that the proposed move is defined in the space of parameters θ , external observable metabolite

¹They are set such that the true value lies within the interval $(\exp(-m\sqrt{\sigma}), \exp(m\sqrt{\sigma}))$ where σ is the log-variance and m is the log-mean. Note that $\exp(\sqrt{0.4805}) \approx 2$ and $\exp(\sqrt{7.6872}) \approx 16$.

concentrations and fluxes y_{ext} , and initial metabolite concentrations x_0 . We use log-normal distributions as the proposal distributions for parameters, external observable variables and the initial concentrations of non-conserved metabolites. The conserved variables, which are a consequence of the conservation of adenine and pyridine nucleotides, have initial concentrations parametrized according to the method described in the Supplementary Material.

The full measurement data are the concentrations of internal glucose, ATP, G6P, ADP, F6P, F16BP, AMP, DHAP, GAP, NAD, BPG, NADH, P3G, P2G, PEP, PYR, acetaldehyde and the fluxes of glucose, glycerol, succinate, pyruvate, glycogen, trehalose. In this model, there are external observable metabolite fluxes y_{ext} namely the measured glycogen and trehalose fluxes.

Sixteen observation datasets are generated using randomly selected parameter values (except in the specific cases discussed below) with the rest of the constants (e.g. equilibrium constants K_{eq} , Michaelis–Menten constants, Hill coefficients) set to the same values as used in Teusink *et al.* (2000). For each case, 30 samples are generated with uniformly distributed initial conditions and with normally distributed glycogen flux and trehalose flux. After the steady-state samples are obtained, additive Gaussian noise is added and the resulting dataset is summarized as a Gaussian distribution.

Using the methodology described in the previous section, MCMC samples are generated to estimate the posterior distribution for each of the datasets. Three parallel chains were used for each case and simulations were run until the sequences converged.

A permutation of 16 sets of resulting MCMC samples with the permutation size of two is used to evaluate the classification method described in Section 2.2. The permutation gives 240 ordered pairs of datasets, from which, the ROC curve that compares the case of being up-regulated and not being up-regulated can be drawn by varying ϵ from -0.5 to 0.5 . Figure 1 shows the ROC curve with the approximate ROC area of 0.836 (the area is estimated based on the trapezoidal area under the curve).

Let us evaluate five out of 16 observation datasets and use the capital letter to indicate each case. The first dataset (Case A) can be regarded as the wild-type yeast, and the rest are *in silico* mutants. All limiting step constants in Case B are lower than those in Case A, while limiting step constants in Case C are higher than those in Case A. The V_{max} values for all five cases are summarized in Table 1. Details of all 16 cases are provided in the Supplementary Material.

Figure 2 shows the result of MCMC for parameter estimation in Case A. The estimation uses the mean of the samples as the estimated parameter for each V_{max}^i and the credible interval is approximated by the 2.5th and 97.5th percentile of the marginalized samples. Figure 2 shows that MCMC is indeed able to produce credible intervals where the true values lie.

The capability of MCMC to produce parameter distribution taking into account uncertainties in the measurement data and in the initial conditions is illustrated in Figure 3 which shows the MCMC samples from Case A. It compares the statistical model of measurement data (which are Gaussian distributions calculated from 30 measurements) with the posterior predictive distribution (i.e. simulated output samples y_{int} using the parameters from MCMC samples).




Fig. 1. ROC curve of MCMC-based perturbations identification using full information (solid line) and using minimal information (dashed line). Circles—maximum accuracy using the weighting ratio ($c_1:c_2$) of 1:1; Triangle—maximum accuracy using the weighting ratio ($c_1:c_2$) of 2:3. The area under the ROC curve for full information is 0.8357 and for minimal information is 0.6114.

Table 1. Limiting step values used in five different simulation setups

| Parameters | Case A | Case B | Case C | Case D | Case E |
|-----------------------|--------|--------|--------|---------|---------|
| V_1^{max} | 101.3 | 81.3 | 121.3 | 110.75 | 120.81 |
| V_2^{max} | 670.5 | 570.5 | 770.5 | 340.83 | 690.77 |
| V_3^{max} | 1933 | 1633 | 2433 | 200.29 | 1270.64 |
| V_4^{max} | 121.5 | 101.5 | 181.5 | 552.06 | 284.36 |
| V_5^{max} | 101 | 81 | 161 | 161.25 | 384.52 |
| $V_7^{\text{f,max}}$ | 2336 | 1336 | 3336 | 2074.87 | 1712.2 |
| $V_7^{\text{r,max}}$ | 3298 | 2298 | 4298 | 3333.92 | 4936.26 |
| V_8^{max} | 2291 | 1291 | 2991 | 958.51 | 819.58 |
| V_9^{max} | 2423 | 1423 | 3223 | 2278.63 | 1494.45 |
| V_{10}^{max} | 240.4 | 180.4 | 290.4 | 238.36 | 297.29 |
| V_{11}^{max} | 700.5 | 650.5 | 790.5 | 790.02 | 816.08 |
| V_{12}^{max} | 869.9 | 809.9 | 969.9 | 1448.25 | 5939.07 |
| V_{13}^{max} | 50.2 | 40.2 | 70.2 | 113.76 | 781.56 |
| V_{14}^{max} | 47.2 | 37.2 | 57.2 | 53.91 | 94.63 |




Fig. 2. Parameter estimation and credible interval in Case A using MCMC. (open square)—the target V_{max} in Case A; (open triangle)—the estimated parameter using the mean of MCMC samples. The credible interval approximation uses the 2.5 and 97.5 percentile sample.




Fig. 3. Plot of the inferred metabolite fluxes and concentrations based on the MCMC samples with full measurement data. (a) Glycogen flux; (b) Pyruvate concentration.




Fig. 4. The plot of (a) $p(V_i, \text{CaseB} > V_i, \text{CaseA})$; (b) $p(V_i, \text{CaseC} > V_i, \text{CaseA})$; (c) $p(V_i, \text{CaseD} > V_i, \text{CaseA})$; (d) $p(V_i, \text{CaseE} > V_i, \text{CaseA})$; using full measurement data. The symbol (\downarrow) or (\uparrow) indicates that the true parameter in the corresponding *in silico* mutant is lower or higher, respectively, than that in the *in silico* wild-type. The classification algorithm with $\varepsilon = 0.0043$ gives the down-regulated region (striped area), up-regulated region (white area) and unchanged region (thick line). The label V_i in the figure corresponds to the limiting-step constant V_{\max}^i (see also Table 1).

The classification algorithm presented in the previous section is used to show whether V_{\max} in the mutant case is higher, relatively constant or lower than that in wild-type case. Using the optimal $\varepsilon = 0.0043$, the resulting classifications are shown in Figure 4.

Figure 4a shows that 13 out of 14 perturbations are correctly predicted by the classification method. When all V_{\max} are up-regulated (Case C), the classification method is able to correctly identify 10 parameter changes with four false negatives. In Cases D and E, where some V_{\max} are increased and some are decreased, the technique yields two and no false positives, respectively. These results show the efficacy of MCMC for identifying mode-of-action given steady-state data of realistic quality.

We now repeat the whole experiment but with limited amounts of measurement data. Instead of having full measurement of metabolite concentrations and fluxes, we seek to infer the parameters based only on the measurement data of the fluxes of glucose, glycerol, succinate and pyruvate.

It is found that the credible intervals obtained from the experiments using minimal informations is typically larger than that obtained from full measurements (data are available




Fig. 5. Plots of the inferred measurement based on the MCMC samples using partial and full information. (a). Pyruvate concentration; (b). ATP concentration.



in the Supplementary Material). This shows that the extent of uncertainties in the parameter estimation increases as the availability of information decreases.

It is interesting to observe that, based on minimal information, we are still able to infer the distribution of some metabolite concentrations and fluxes that are not available in the measurement data. Figure 5 shows the measurement data for (a) pyruvate and (b) ATP concentrations in Case A along with the inferred pyruvate and ATP concentration obtained from the MCMC simulation using full information and using minimal information. The inference using minimal information is able to estimate the uncertainties reasonably well, although information scarcity produces a long-tail distribution as shown in Figure 5a. The discrepancy of the measured distribution of ATP concentration with the inferred one using full information suggests that measurement noise has a significant contribution to the uncertainties in the measurement data which cannot be explained by parameter uncertainties alone.

The ROC curve for perturbation identification using minimal information is shown in Figure 1. The area under the curve is 0.611 which is considerably lower than that obtained using full information. Due to this relatively poor performance, the optimal ε is computed using the ratio $c_1:c_2$ of 2:3 which puts higher weight on specificity. Based on this ratio, the optimal ε is 0.0465 with a specificity of 0.9075 and a sensitivity of 0.1928. In the following subsection, we use this optimal value for the analysis of perturbations in pyruvate pathways of *L.lactis* where the experimental data are minimal. In general the correct balance between specificity and sensitivity will depend on the application.

3.2 Pyruvate pathways in *L.lactis*

In this section, we try to identify the perturbation in the lactic acid bacteria represented by the removal of lactate dehydrogenase and the over-expression of NADH oxidase. The experimental data are taken from Hoefnagel *et al.* (2002) and the corresponding pathways are shown in Figure 6. Comparing our model with that in Hoefnagel *et al.* (2002), our model contains an additional pyruvate carboxylase reaction which can serve as an alternative branch for the production of phosphoenolpyruvate. The branch is added to explain the missing carbon flux in the experimental data. In addition to the rate equations used in Hoefnagel *et al.* (2002), the rate equation for pyruvate carboxylase is given by $v_{14} = V_{\max}^{14} [\text{pyruvate}] / (K_m + [\text{pyruvate}])$ where K_m is 0.31 mM (Sueda *et al.*, 2004).



This article focuses on the application of MCMC to parameter estimation and perturbation analysis in metabolic pathways. Compared to the existing literature, the technique developed

in this article has three distinguishing features. First, the systems are described by first-order non-linear ODEs subject to algebraic constraints corresponding to the moiety conservations. Secondly, it focuses on steady-state measurement data without any information about the sampling time. Thirdly, it copes with observable external variables that are not components of the state vector but that do appear in the non-linear ODEs.

The ability to produce a broad credible region in parameter space is a feature distinguishing MCMC-based parameter estimation from most parameter identification techniques. This complements the standard parameter fitting methods, such as genetic or gradient descent-based algorithms, which can be used to obtain a point estimate of the model parameters and for which the credibility of estimated parameters is less easily assessed. Approaches for estimating credible intervals based on expansions around a point estimate, using e.g. the Hessian of the log-likelihood, are essentially asymptotic in the size of dataset and work under the assumption that the posterior distribution can be well-approximated by a Gaussian distribution. In the examples considered here, data were very limited and therefore the credible intervals obtained were broad and asymmetrical, reflecting the non-Gaussian nature of the posterior distribution. The posterior distribution also allows for the investigation of higher order relationships between parameters, e.g. the correlation or mutual information between parameters (Lüdtke *et al.*, 2008). We have not pursued this here, as we have focused only on changes in the marginal distribution of each parameter. In addition, we have confined these studies to two comparatively small systems, and future work will determine the extent to which these methods scale to larger networks.

The perturbation analyses are done via a simple classification algorithm applied to MCMC samples from the two cases. The algorithm relies on a parameter ε which can be selected based on simulated cases. It can be chosen at an appropriate level depending on the availability of measurement data and in order to balance specificity and sensitivity.

Our analysis of measurement data from three strains of *L.lactis* gives insights into the possible pleiotropic effects due to genetic modification. It also confirms that the mutants have major alterations in the known target reactions.

ACKNOWLEDGEMENTS

The authors wish to thank Dr Joshua Knowles for many useful discussions and Dr Simon Rogers for the technical advice on the proposal distributions.

Funding: This study was funded by UK Biotechnology and Biological Sciences Research Council (BB/E016065).

Conflicts of Interest: none declared.

REFERENCES

- Aranibar, N. *et al.* (2001) Automated mode-of-action detection by metabolic profiling. *Biochem. Biophys. Res. Commun.*, **286**, 150–155.
- Baetz, K. *et al.* (2004) Yeast genome-wide drug-induced haploinsufficiency screen to determine drug mode of action. *Proc. Natl Acad. Sci. USA*, **101**, 4525–4530.
- Battogtokh, D. *et al.* (2002) An ensemble method for identifying regulatory circuits with special reference to the qa gene cluster of *Neurospora crassa*. *Proc. Natl Acad. Sci. USA*, **99**, 16904–16909.
- Betts, J.C. *et al.* (2002) Evaluation of a nutrient starvation model of *Mycobacterium tuberculosis* persistence by gene and protein expression profiling. *Mol. Microbiol.*, **43**, 717–731.
- Broadhurst, D. and Kell, D.B. (2006) Statistical strategies for avoiding false discoveries in metabolomics and related experiments. *Metabolomics*, **2**, 171–196.
- Butcher, E.C. (2005) Can cell systems biology rescue drug discovery? *Nat. Rev. Drug Discov.*, **4**, 461–467.
- Chapal, N. *et al.* (2004) Pharmacoproteomic approach to the study of drug mode of action, toxicity, and resistance: applications in diabetes and cancer. *Fund. Clin. Pharmacol.*, **18**, 413–422.
- Clarke, P.A. *et al.* (2001) Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential. *Biochem. Pharmacol.*, **62**, 1311–1336.
- Coleman, M.C. and Block, D.E. (2006) Bayesian parameter estimation with informative priors for nonlinear systems. *Aiche J.*, **52**, 651–667.
- Davey, H.M. and Kell, D.B. (1996) Flow cytometry and cell sorting of heterogeneous microbial populations: the importance of single-cell analysis. *Microbiol. Rev.*, **60**, 641–696.
- Koning, W. and van Dam, K. (1992) A method for the determination of changes of glycolytic metabolites in yeast on a subsecond time scale using extraction at neutral pH. *Anal. Biochem.*, **204**, 118–123.
- Dobson, P.D. and Kell, D.B. (2008) Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? *Nat. Rev. Drug Discov.*, **7**, 205–220, doi:10.1038/nrd2438.
- Gelman, A. (2004) Bayesian data analysis. Chapman & Hall/CRC, Boca Raton, Florida, London.
- Giaever, G. *et al.* (1999) Genomic profiling of drug sensitivities via induced haploinsufficiency. *Nat. Genet.*, **21**, 278–283.
- Hoefnagel, M.H.N. *et al.* (2002) Metabolic engineering of lactic acid bacteria, the combined approach: kinetic modelling, metabolic control and experimental analysis. *Microbiol.-Sgm*, **148**, 1003–1013.
- Hofmeyr, J.H. *et al.* (1986) Metabolic control analysis of moiety-conserved cycles. *Eur. J. Biochem.*, **155**, 631–641.
- Kell, D.B. (2006) Systems biology, metabolic modelling and metabolomics in drug discovery and development. *Drug Discov. Today*, **11**, 1085–1092.
- Liebermeister, W. and Klipp, E. (2006) Bringing metabolic networks to life: integration of kinetic, metabolic, and proteomic data. *Theor. Biol. Med. Mod.*, **3**, 42.
- Liu, X.J. *et al.* (2006) Probe-level measurement error improves accuracy in detecting differential gene expression. *Bioinformatics*, **22**, 2107–2113.
- Lüdtke, N. *et al.* (2008) Information-theoretic Sensitivity Analysis: a general method for credit assignment in complex networks. *J. Roy. Soc. Interface*, **5**, 223–235.
- Marton, M.J. *et al.* (1998) Drug target validation and identification of secondary drug target effects using DNA microarrays. *Nat. Med.*, **4**, 1293–1301.
- Ott, K.H. *et al.* (2003) Metabonomics classifies pathways affected by bioactive compounds. Artificial neural network classification of NMR spectra of plant extracts. *Phytochemistry*, **62**, 971–985.
- Parsons, A.B. *et al.* (2004) Integration of chemical-genetic and genetic interaction data links bioactive compounds to cellular target pathways. *Nat. Biotechnol.*, **22**, 62–69.
- Parsons, A.B. *et al.* (2006) Exploring the mode-of-action of bioactive compounds by chemical-genetic profiling in yeast. *Cell*, **126**, 611–625.
- Pritchard, L. and Kell, D.B. (2002) Schemes of flux control in a model of *Saccharomyces cerevisiae* glycolysis. *Eur. J. Biochem.*, **269**, 3894–3904.
- Spiegelhalter, W.R. *et al.* (1996) *Markov chain Monte Carlo in Practice*. Chapman & Hall, London.
- Sueda, S. *et al.* (2004) Protein engineering of pyruvate carboxylase: investigation on the function of acetyl-CoA and the quaternary structure. *Eur. J. Biochem.*, **271**, 1391–1400.
- Tamaddon-Nezhad, A. *et al.* (2006) Application of abductive ILP to learning metabolic network inhibition from temporal data. *Mach. Learn.*, **64**, 209–230.
- Teusink, B. *et al.* (2000) Can yeast glycolysis be understood in terms of in vitro kinetics of the constituent enzymes? Testing biochemistry. *Eur. J. Biochem.*, **267**, 5313–5329.
- Vyshemirsky, V. and Girolami, M.A. (2007) Bayesian Ranking of Biochemical System Models. *Bioinformatics*, doi:10.1093/bioinformatics/btm607.
- Williams, M. (2005) Systems and integrative biology as alternative guises for pharmacology: prime time for an iPharm concept? *Biochem. Pharmacol.*, **70**, 1707–1716.